Author’s response to reviews

Title: Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.

Authors:

Alessandro Ciresi (a.ciresi@virgilio.it)
Stefano Radellini (rdlsfn@gmail.com)
Valentina Guarnotta (valentinaguarinotta@gmail.com)
Carla Giordano (carla.giordano@unipa.it)

Version: 2 Date: 03 Jan 2018

Author’s response to reviews:

1) Ethics approval and consent to participate: as this is a case report, it is unusual for ethics approval to have been sought. If approval has been sought, please retain this information. In addition, the consent information is usually provided in the consent for publication heading - please move accordingly (see below).

Reply: Done, as suggested (lines 106-107).

2) Consent for publication: the wording often used for this section is as follows -

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Reply: Done, as suggested (lines 106-107 and 258-259).

3) Supplementary table 1 (time line table): please advise whether this is for publication or was provided for the reviewers only. If to accompany the published version, please could the table be cited in an appropriate place within the text and a summary title provided in the main word file (alongside the titles for Figure 1)

Reply: This table was made in accordance with the Journal’s Guidelines for the Case Reports. However, it does not need to be published.

Reply to Reviewers:

Reviewer reports:

Marinela Tzanella (Reviewer 1):
Dear colleagues

All issues addressed are promptly addressed, therefore I recommend that the manuscript is suitable for publication

----

Adriana Ioachimescu (Reviewer 2): It sounds like a case where a triple regimen of pasireotide, pegvisomant and cabergoline worked.

Please change the title and abstract that it reflects this situation, especially for a mixed GH-PRL tumor.

Reply: In agreement with this observations, we partially modified the Title and Abstract (line 51-52 and 54) of the manuscript.